ITCI
NASDAQIntra-Cellular Therapies Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- PRPhathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateVOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali
- SECSEC Form 15-12G filed by Intra-Cellular Therapies Inc.15-12G - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form EFFECT filed by Intra-Cellular Therapies Inc.EFFECT - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- INSIDERDirector Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERDirector Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERPresident Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERDirector Van Nostrand Robert L returned $1,496,880 worth of shares to the company (11,340 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDEREVP, Chief Commercial Officer Neumann Mark returned $6,971,052 worth of shares to the company (52,811 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERDirector Marcus Joel S returned $7,687,416 worth of shares to the company (58,238 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERChairman and CEO Mates Sharon returned $149,851,020 worth of shares to the company (1,135,235 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDEREVP, Chief Medical Officer Durgam Suresh K. returned $5,664,516 worth of shares to the company (42,913 units at $132.00), closing all direct ownership in the company (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President & CFO Narula Sanjeev4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- SECSEC Form POSASR filed by Intra-Cellular Therapies Inc.POSASR - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form S-8 POS filed by Intra-Cellular Therapies Inc.S-8 POS - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form POS AM filed by Intra-Cellular Therapies Inc.POS AM - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECIntra-Cellular Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECSEC Form 25-NSE filed by Intra-Cellular Therapies Inc.25-NSE - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
- INSIDERChairman and CEO Mates Sharon gifted 190,000 shares and received a gift of 190,000 shares, decreasing direct ownership by 17% to 945,235 units (SEC Form 4)4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
- SECSEC Form 8-K filed by Intra-Cellular Therapies Inc.8-K - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Intra-Cellular Therapies Inc.10-K/A - Intra-Cellular Therapies, Inc. (0001567514) (Filer)
ITCI FAQ
6 questionsWhat does Intra-Cellular Therapies Inc. do?
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits...Where does ITCI stock trade?
Intra-Cellular Therapies Inc. (ITCI) is listed on NASDAQ.What sector and industry is ITCI in?
Intra-Cellular Therapies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ITCI?
Intra-Cellular Therapies Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Neutral on 2025-02-24. Recent price targets cluster around $4900.00.What companies are similar to ITCI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ITCI side-by-side with any of them on Quantisnow.How can I track ITCI on Quantisnow?
Quantisnow aggregates Intra-Cellular Therapies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ITCI to receive live email and push alerts on every new disclosure.